News

Filter News By

Clear Filters

  1. Cystic Fibrosis Foundation Is Exploring New CFTR Modulators

    October 24, 2019

    The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.

  2. CF Foundation Celebrates FDA Approval of Triple Combination

    October 21, 2019

    The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.

  3. Enterprise Therapeutics Awarded Up to $7M to Develop Mucus-Clearance Drug for People With CF

    October 15, 2019

    The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.

    Topics:

  4. ICER Posts Draft Scoping Document for Assessment of Triple Combination Therapy

    October 15, 2019

    The Institute for Clinical and Economic Review (ICER) recently posted a draft scoping document to outline their planned assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The document is open for public comment through October 21.

    Topics:

  5. Foundation Funds Early Stage Clinical Trial of a Potential Nonsense Mutation Treatment

    September 23, 2019

    The Cystic Fibrosis Foundation awarded up to $1.61 million to Eloxx Pharmaceuticals Inc. to conduct a U.S.-based Phase 2 clinical trial of an investigational drug that could potentially treat people with cystic fibrosis who have a nonsense mutation.

    Topics:

  6. ICER Announces Assessment of Triple-Combination Therapy

    September 13, 2019

    The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The first opportunity to comment runs through Sept. 25.

    Topics:

  7. The CF Foundation Awards Arcturus Therapeutics Up to $15M for RNA Therapy

    August 5, 2019

    The Cystic Fibrosis Foundation has increased its award to Arcturus Therapeutics to up to $15 million to develop a mutation-agnostic therapy for people with cystic fibrosis.

  8. Merrill/Bank of America Raises More Than $32,000 Through Matching Gifts

    July 26, 2019

    To support a pair of colleagues’ adoption of a baby boy, Christian, Merrill/Bank of America has raised more than $32,000 through their matching gifts program.

    Topics:

  9. CF Foundation Announces 2019 Impact Grant Recipients

    July 23, 2019

    Recipients include five innovative programs from around the country that empower the CF community.

  10. Application for Triple-Combination Therapy Submitted to the FDA

    July 22, 2019

    Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.

  11. Rep. Mark Amodei Announced as New Co-Chair of Congressional CF Caucus

    July 12, 2019

    U.S. Rep. Mark Amodei of Nevada will join fellow Rep. Jim McGovern and Sens. Chuck Grassley and Ed Markey in co-chairing the Congressional Cystic Fibrosis Caucus, championing awareness of the rare disease and the Cystic Fibrosis Foundation’s search for a cure.

    Topics:

  12. Nearly 200 Volunteers Advocate for Loved Ones During 11th Annual Teen Advocacy Day

    July 2, 2019

    Nearly 200 people from across the country -- including teens from 38 states -- came to Washington, D.C., on June 27 to advocate for the needs of their loved ones living with cystic fibrosis during the Cystic Fibrosis Foundation’s 11th Annual Teen Advocacy Day.

    Topics:

More Posts View All Posts

Follow Us On